Plasma fluvoxamine levels and OCD symptoms/response in adult patients

Human Psychopharmacology

Volumn 27, Issue 4, 2012, Pages 397-402

  Marazziti, Donatella ^a   Baroni, Stefano ^a   Giannaccini, Gino ^a   Piccinni, Armando ^a   Picchetti, Michela ^a   Massimetti, Gabriele ^a   Schiavi, Elisa ^a   Palego, Lionella ^a   Catena Dell'Osso, Mario ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

drug metabolism; fluvoxamine; HPLC; obsessive compulsive disorder; plasma levels; Y BOCS

Indexed keywords

FLUVOXAMINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; COMPULSION; DISEASE SEVERITY; DRUG BLOOD LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; PRIORITY JOURNAL; RATING SCALE; SEX DIFFERENCE; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; FLUVOXAMINE; FOLLOW-UP STUDIES; HUMANS; MALE; OBSESSIVE-COMPULSIVE DISORDER; OUTPATIENTS; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX; SEX FACTORS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84864126661     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.2240     Document Type: Article

References (50)

1. Ackerman DL, Greenland S,. 2002. Multivariate meta-analysis of controlled drug studies for obsessive-compulsive disorder. J Clin Psychopharmacology 22: 309-317.
2. Ago Y, Yano K, Hiramatsu N, Takuma K, Matsuda T,. 2011. Fluvoxamine enhances prefrontal dopaminergic neurotransmission in adrenalectomized/castrated mice via both 5-HT reuptake inhibition and ï (1) receptor activation. Psychopharmacology 217: 377-386.
3. American Psychiatric Association. 2000. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Text Revision (DSM-IV-TR). American Psychiatric Press: Washington DC.
4. Bandelow B,. 2008. The medical treatment of obsessive-compulsive disorder and anxiety. CNS Spectr 13: 37-46.
5. Bareggi SR, Mundo E, Dell'Osso B, Altamura AC,. 2007. The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders. Expert Opin Drug Metab Toxicol 3: 741-753.
6. Baumann P, Ulrich S, Eckermann G, et al,. 2005. Arbeitsgemeinschaft fur neuropsychopharmakologie und pharmakopsyhiatrie-therapeutic drug monitoring group. The AGNP-TDM expert group consensus guidelines: focus on therapeutic monitoring of antidepressants. Dialogues Clin Neurosci 7: 231-247.
7. Benkert O, Szegedi A, Wetzel H,. 1996. Minimum effective dose for antidepressants-an obligatory requirement for antidepressant drug evaluation? Int Clin Psychopharmacology 11: 177-185.
8. Charlier C, Pinto E, Ansseau M, Plomteux G,. 2000. Relationship between clinical effects, serum drug concentration, and concurrent drug interactions in depressed patients treated with citalopram, fluoxetine, clomipramine, paroxetine or venlafaxine. Hum Psychopharmacol 15 (6): 453-459.
9. Cottraux J, Mollard E, Bouvard M, Marks I,. 1993. Exposure therapy, fluvoxamine, or combination treatment in obsessive-compulsive disorder: one-year followup. Psychiatry Res 49: 63-75.
10. DeVane CL,. 1998. Differential pharmacology of newer antidepressants. J Clin Psychiatry 59 (Suppl 20): 85-93.
11. Fineberg NA, Gale TM,. 2005. Evidence-based pharmacotherapy of obsessive-compulsive disorder. Int J Neuropsychopharmacology 8: 107-129.
12. First MB, Spitzer RL, Gibbon M, Williams JBW,. 1997. Structured Clinical Interview for DSM-IV Axis I Disorders-Patient Edition (SCID-I P, Version 2.0, 4 97 revision). Biometrics Research, New York State Psychiatric Institute: New York, NY.
13. Goodman WK, Price LH, Rasmussen SA, Delgado PL, Heninger GR, Charney DS,. 1989a. Efficacy of fluvoxamine in obsessive-compulsive disorder. A double- blind comparison with placebo. Arch Gen Psychiatry 46: 36-44.
14. Goodman WK, Price LH, Rasmussen SA, et al,. 1989b. The Yale-Brown Obsessive Compulsive Scale. II. Validity. Arch Gen Psychiatry 46: 1012-1016.
15. Goodman WK, Price LH, Rasmussen SA, et al,. 1989c. The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry 46: 1006-1011.
16. Goodman WK, Kozak MJ, Liebowitz M, White KL,. 1996. Treatment of obsessive-compulsive disorder with fluvoxamine: a multicentre, double-blind, placebo-controlled trial. Int Clin Psychopharmacol 11: 21-9.
17. Hamilton M,. 1960. A rating scale for depression. J Neurol Neurosurg Psychiatry 23: 56-61.
18. van Harten J,. 1995. Overview of the pharmacokinetics of fluvoxamine. Clin Pharmacokinet 29 (Suppl 1): 1-9.
19. Härtter S, Wetzel H, Hiemke C,. 1992. Automated determination of fluvoxamine in plasma by column-switching high-performance liquid chromatography. Clin Chem 38 (10): 2082-2086
20. Hiemke C,. 2008. Therapeutic drug monitoring in neuropsychopharmacology: does it hold its promises? Eur Arch Psychiatry Clin Neurosci 258: 21-27.
21. Hohagen F, Winkelmann G, Rasche-Rüchle H, et al,. 1998. Combination of behaviour therapy with fluvoxamine in comparison with behaviour therapy and placebo. Results of a multicentre study. Br J Psychiatry Suppl 35: 71-8.
22. Hollander E, Koran LM, Goodman WK, et al,. 2003. A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder. J Clin Psychiatry 64 (6): 640-7.
23. Hyttel J,. 1993. Comparative pharmacology of selective serotonin reuptake inhibitors (SSRIs). Nord J Psychiatry 47 (Suppl 30): 5-12.
24. Insel TR, Murphy DL, Cohen RM, Alterman I, Kilts C, Linnoila M,. 1983. Obsessive-compulsive disorder. A double-blind trial of clomipramine and clorgyline. Arch Gen Psychiatry 40 (6): 605-612.
25. Kasper S, Dötsch M, Kick H, Vieira A, Möller HJ,. 1993. Plasma concentrations of fluvoxamine and maprotiline in major depression: implications on therapeutic efficacy and side effects. Eur Neuropsychopharmacol 3 (1): 13-21.
26. Kasvikis Y, Marks IM,. 1988. Clomipramine in obsessive-compulsive ritualisers treated with exposure therapy: relations between dose, plasma levels, outcome and side effects. Psychopharmacology (Berl). 95 (1): 113-118.
27. Leonard B,. 1992. Pharmacological differences of serotonin reuptake inhibitors and possible clinical relevance. Drugs 43 (Suppl 2): 3-10.
28. Mallya GK, White K, Waternaux C, Christine QS,. 1992. Short and long-term treatment of obsessive-compulsive disorder with fluvoxamine. Ann Clin Psychiatry 4: 77-80.
29. Marazziti D, Consoli G,. 2010. Treatment strategies for obsessive-compulsive disorder. Expert Opin Pharmacother 11: 331-343.
30. Marazziti D, Consoli G, Baroni S, Catena Dell'Osso M,. 2010. Past, present and future drugs for the treatment of obsessive-compulsive disorder. Curr Med Chem 17: 3410-3421.
31. Marazziti D, Baroni S, Faravelli L, Giannaccini G, Massimetti G, Palego L, Catena-Dell'Osso M,. 2012. Plasma clomipramine levels in adult patients with obsessive-compulsive disorder. Int Clin Psychopharmacol. 27 (1): 55-60.
32. Mavissakalian MR, Jones B, Olson S, Perel JM,. 1990. Clomipramine in obsessive-compulsive disorder: clinical response and plasma levels. J Clin Psychopharmacol. 10 (4): 261-268.
33. Milanfranchi A, Ravagli S, Lensi P, Marazziti D, Cassano GB,. 1997. A double-blind study of fluvoxamine and clomipramine in the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol 12: 131-6.
34. Moresco RM, Pietra L, Henin M, et al,. 2007. Fluvoxamnine treatment and D2 receptors: a pet study on OCD drug-naive patients. Neuropsychopharmacology 32: 197-205.
35. Mundo E, Rouillon F, Figuera ML, Stigler M,. 2001. Fluvoxamine in obsessive-compulsive disorder: similar efficacy but superior tolerability in comparison with clomipramine. Hum Psychopharmacol 16 (6): 461-8.
36. Ordacgi L, Mendlowicz MV, Fontenelle LF,. 2009. Management of obsessive-compulsive disorder with fluvoxamine extended release. Neuropsychiatr Dis Treat 5: 301-8.
37. Overmars H, Scherpenisse PM, Post LC,. 1983. Fluvoxamine maleate: metabolism in man. Eur J Drug Metab Pharmacokinet 8: 269-80.
38. Owen RT,. 2008. Controlled-release fluvoxamine in obsessive-compulsive disorder and social phobia. Drugs Today (Barc) 44 (12: 887-93.
39. Palego L, Marazziti D, Biondi L, et al,. 2000. Simultaneous plasma level analysis of clomipramine, N-desmethylclomipramine, and fluvoxamine by reversed-phase liquid chromatography. Ther Drug Monit 22: 190-194.
40. Pallanti S, Hollander E, Bienstock C, et al,. 2002. Treatment non-response in OCD: methological issues and operational definitions. Int J Neuropsychopharmacol 5: 181-189.
41. Perry PJ, Zeilmann C, Arndt S,. 1994. Tricyclic antidepressant concentrations in plasma: an estimate of their sensitivity and specificity as a predictor of response. J Clin Psychopharmacology 14: 230-240.
42. Preskorn SH, Fast GA,. 1991. Therapeutic drug monitoring for antidepressants: efficacy, safety, and cost effectiveness. J Clin Psychiatry 52: 23-33.
43. Simpson HB, Huppert JD, Petkova E, Foa EB, Liebowitz MR,. 2006. Response versus treatment in obsessive-compulsive disorder. J Clin Psychiatry 67: 269-276.
44. Stephan PL, Etzensberger M, Jaquenoud Sirot E,. 2006. Therapeutic drug monitoring: a pharmacotherapeutic tool in psychiatry. Praxis (Bern 1994) 26: 671-678.
45. Stern RS, Cobb JP, Marks IM, Jones RB, Luscombe DK,. 1977. A preliminary report on clinical response and plasma levels of clomipramine and desmethylclomipramine in obsessive-compulsive neurosis. Postgrad Med J 53: 97-103.
46. Strauss WL, Layton ME, Hayes CE, Dager SR,. 1997. 19F magnetic resonance spectroscopy investigation in vivo of acute and steady state brain fluvoxamine levels in obsessive-compulsive disorder. Am J Psychiatry 14: 516-522.
47. Tolin DF, Abramowitz JS, Diefenbach GJ,. 2005. Defining response in clinical trials for obsessive-compulsive disorder: a signal detection of the Yale-Brown obsessive-compulsive scale. J Clin Psychiatry 66: 1549-1557.
48. Vandel S, Bertschy G, Vandel B, Allers G, Volmat R,. 1990. Nonlinear kinetics of nortriptyline in every day practice. Eur J Clin Pharmacol. 39 (1): 97-98.
49. Vuille F, Amey M, Baumann P,. 1991. Use of plasma level monitoring of antidepressants in clinical practice. Towards an analysis of clinical utility. Pharmacopsychiatry 24 (6): 190-195.
50. Wong SH, Kranzler HR, DellaFera S, Fernandes R,. 1994. Determination of fluvoxamine concentration in plasma by reversed-phase liquid chromatography. Biomed Chromatogr 8: 278-282.